Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
EDQM
0
USP
0
JP
0
Others
0
FDA Orange Book
0
Canada
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. (+)-(2s)-2-((s)-(2-ethoxyphenoxy)phenylmethyl)morpholine
1. (s,s)-reboxetine
2. 98819-76-2
3. S,s-reboxetine
4. (2s)-2-[(s)-(2-ethoxyphenoxy)-phenylmethyl]morpholine
5. L8s50zy490
6. (2s)-2-[(s)-2-ethoxyphenoxy(phenyl)methyl]morpholine
7. (s)-2-((s)-(2-ethoxyphenoxy)(phenyl)methyl)morpholine
8. (+)-(2s)-2-((s)-(2-ethoxyphenoxy)phenylmethyl)morpholine
9. Morpholine, 2-((s)-(2-ethoxyphenoxy)phenylmethyl)-, (2s)-
10. Esreboxetine [usan]
11. Esreboxetine (usan/inn)
12. Esreboxetine [usan:inn]
13. Unii-l8s50zy490
14. S-reboxetine
15. Pnu 165442g
16. Tocris-1982
17. Ncgc00025335-01
18. Esreboxetine [inn]
19. (s,s)-(+)-reboxetine
20. Schembl34534
21. Esreboxetine [who-dd]
22. Chembl180101
23. Gtpl4808
24. Zinc6923
25. Bdbm35226
26. (2s)-2-[(s)-(2-ethoxyphenoxy)-phenyl-methyl]morpholine
27. Chebi:125535
28. Dtxsid601009938
29. Db12395
30. D09340
31. 819s762
32. Q5399299
33. Brd-k32814891-001-01-1
| Molecular Weight | 313.4 g/mol |
|---|---|
| Molecular Formula | C19H23NO3 |
| XLogP3 | 3 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 4 |
| Rotatable Bond Count | 6 |
| Exact Mass | 313.16779360 g/mol |
| Monoisotopic Mass | 313.16779360 g/mol |
| Topological Polar Surface Area | 39.7 Ų |
| Heavy Atom Count | 23 |
| Formal Charge | 0 |
| Complexity | 333 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 2 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Reboxetine has known human metabolites that include O-desethylreboxetine, Phenol A, and Phenol B.
S73 | METXBIODB | Metabolite Reaction Database from BioTransformer | DOI:10.5281/zenodo.4056560
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Listed Suppliers
About the Company : Shouyuan chemical (one of the leading chemicals supplier in China) specializes in manufacturing, supplying, and custom synsthesis latest chemicals. Our products cover all kinds of ...
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Drugs in Development
Details:
AXS-12 (reboxetine) is a highly selective and potent norepinephrine reuptake inhibitor and cortical dopamine modulator. It is being evaluated for the treatment of Narcolepsy.
Lead Product(s): Reboxetine Mesylate
Therapeutic Area: Sleep Brand Name: AXS-12
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 26, 2024
Lead Product(s) : Reboxetine Mesylate
Therapeutic Area : Sleep
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Axsome’s AXS-12 Meets Primary Endpoint in ENCORE Narcolepsy Phase 3 Trial
Details : AXS-12 (reboxetine) is a highly selective and potent norepinephrine reuptake inhibitor and cortical dopamine modulator. It is being evaluated for the treatment of Narcolepsy.
Product Name : AXS-12
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 26, 2024
Details:
AXS-12 (reboxetine) is a highly selective and potent norepinephrine reuptake inhibitor and cortical dopamine modulator. It is being evaluated for the treatment of Narcolepsy.
Lead Product(s): Reboxetine Mesylate
Therapeutic Area: Sleep Brand Name: AXS-12
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 25, 2024
Lead Product(s) : Reboxetine Mesylate
Therapeutic Area : Sleep
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in SYMPHONY Phase 3 Trial
Details : AXS-12 (reboxetine) is a highly selective and potent norepinephrine reuptake inhibitor and cortical dopamine modulator. It is being evaluated for the treatment of Narcolepsy.
Product Name : AXS-12
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 25, 2024
Details:
AXS-14 (esreboxetine) is a highly selective and potent norepinephrine reuptake inhibitor for the management of fibromyalgia and other conditions. Submission anticipated in 4Q 2022. Acceptance of the NDA will be subject to the FDA’s review of the complete filing.
Lead Product(s): Reboxetine Mesylate
Therapeutic Area: Musculoskeletal Brand Name: AXS-12
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 15, 2021
Lead Product(s) : Reboxetine Mesylate
Therapeutic Area : Musculoskeletal
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Axsome Therapeutics to Submit NDA to US FDA for AXS-14 for Management of Fibromyalgia
Details : AXS-14 (esreboxetine) is a highly selective and potent norepinephrine reuptake inhibitor for the management of fibromyalgia and other conditions. Submission anticipated in 4Q 2022. Acceptance of the NDA will be subject to the FDA’s review of th...
Product Name : AXS-12
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 15, 2021
Details:
Apnimed’s lead product candidate, AD109, targets the neurologic control and facilitates the activation of the upper airway dilator muscles to maintain an open airway during sleep.
Lead Product(s): Reboxetine Mesylate,Oxybutynin
Therapeutic Area: Sleep Brand Name: AD128
Study Phase: Phase II/ Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 17, 2021
Lead Product(s) : Reboxetine Mesylate,Oxybutynin
Therapeutic Area : Sleep
Highest Development Status : Phase II/ Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Apnimed’s lead product candidate, AD109, targets the neurologic control and facilitates the activation of the upper airway dilator muscles to maintain an open airway during sleep.
Product Name : AD128
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 17, 2021
Details:
The expedited development plan includes one Phase 3 efficacy trial, which, along with the previously completed Phase 2 CONCERT trial, will be used to support the filing of an NDA (New Drug Application) for approval of AXS-12 for the treatment of cataplexy in narcolepsy.
Lead Product(s): Reboxetine Mesylate
Therapeutic Area: Sleep Brand Name: AXS-12
Study Phase: Phase IIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 21, 2020
Lead Product(s) : Reboxetine Mesylate
Therapeutic Area : Sleep
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The expedited development plan includes one Phase 3 efficacy trial, which, along with the previously completed Phase 2 CONCERT trial, will be used to support the filing of an NDA (New Drug Application) for approval of AXS-12 for the treatment of cataplex...
Product Name : AXS-12
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 21, 2020
Details:
Axsome will present efficacy & safety data from the CONCERT Ph 2 trial of AXS-12 in the treatment of narcolepsy at the 34th Annual SLEEP Meeting of the APSS. AXS-12 is a novel, oral, highly selective and potent norepinephrine reuptake inhibitor for the treatment of narcolepsy.
Lead Product(s): Reboxetine Mesylate
Therapeutic Area: Sleep Brand Name: AXS-12
Study Phase: Phase IIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 28, 2020
Lead Product(s) : Reboxetine Mesylate
Therapeutic Area : Sleep
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Axsome will present efficacy & safety data from the CONCERT Ph 2 trial of AXS-12 in the treatment of narcolepsy at the 34th Annual SLEEP Meeting of the APSS. AXS-12 is a novel, oral, highly selective and potent norepinephrine reuptake inhibitor for the t...
Product Name : AXS-12
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 28, 2020
Details:
AXS-12 is a novel, oral, highly selective and potent norepinephrine reuptake inhibitor. Axsome previously received Orphan Drug Designation from the FDA for AXS-12 for the treatment of narcolepsy.
Lead Product(s): Reboxetine Mesylate
Therapeutic Area: Sleep Brand Name: AXS-12
Study Phase: Phase IIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 08, 2020
Lead Product(s) : Reboxetine Mesylate
Therapeutic Area : Sleep
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AXS-12 is a novel, oral, highly selective and potent norepinephrine reuptake inhibitor. Axsome previously received Orphan Drug Designation from the FDA for AXS-12 for the treatment of narcolepsy.
Product Name : AXS-12
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 08, 2020
Details:
Agreement accelerates ongoing clinical development of AXS-12 (reboxetine) in narcolepsy which expands Axsome’s pipeline with new Phase 3-stage esreboxetine product candidate for fibromyalgia
Lead Product(s): Reboxetine Mesylate
Therapeutic Area: Sleep Brand Name: AXS-12
Study Phase: Phase IIProduct Type: Other Small Molecule
Sponsor: Axsome Therapeutics
Deal Size: $331.0 million Upfront Cash: $3.0 million
Deal Type: Licensing Agreement January 13, 2020
Lead Product(s) : Reboxetine Mesylate
Therapeutic Area : Sleep
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Axsome Therapeutics
Deal Size : $331.0 million
Deal Type : Licensing Agreement
Axsome Therapeutics Enters into Exclusive License Agreement with Pfizer Inc. for Pfizer’s Reboxe...
Details : Agreement accelerates ongoing clinical development of AXS-12 (reboxetine) in narcolepsy which expands Axsome’s pipeline with new Phase 3-stage esreboxetine product candidate for fibromyalgia
Product Name : AXS-12
Product Type : Other Small Molecule
Upfront Cash : $3.0 million
January 13, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
Regulatory Info :
Registration Country : Sweden
Brand Name : Edronax
Dosage Form : TABLETT
Dosage Strength : 4 MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Sweden
Regulatory Info :
Registration Country : Sweden
Brand Name : reboxetine
Dosage Form : TABLET
Dosage Strength : 4 MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Sweden
Regulatory Info :
Registration Country : Sweden
Brand Name : reboxetine
Dosage Form : TABLET
Dosage Strength : 4 MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Sweden
Regulatory Info :
Registration Country : Australia
Brand Name : Edronax
Dosage Form : tablet
Dosage Strength : 4 mg
Packaging : 60
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Australia
Regulatory Info :
Registration Country : Italy
Brand Name : Edronax
Dosage Form : Reboxetine 4Mg 20 Joined' Oral Use
Dosage Strength : 20 CPR 4 mg
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Regulatory Info :
Registration Country : Switzerland
Brand Name : Edronax
Dosage Form : Tabl
Dosage Strength : 4mg
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
Regulatory Info :
Registration Country : Sweden
Brand Name : reboxetine
Dosage Form : TABLET
Dosage Strength : 4 MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Sweden
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Regulatory Info :
Registration Country : Sweden
Brand Name : reboxetine
Dosage Form : TABLET
Dosage Strength : 4 MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Sweden
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Regulatory Info :
Registration Country : Sweden
Brand Name : Edronax
Dosage Form : TABLETT
Dosage Strength : 4 MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Sweden
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Regulatory Info :
Registration Country : Spain
Brand Name : Irenor 4Mg 20 Tablets
Dosage Form : Tablet
Dosage Strength : 4 Mg/Tablet
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Spain
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
Global Sales Information
Market Place
APIs
Reply
04 Mar 2022
Reply
06 Jul 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
ABOUT THIS PAGE
55
PharmaCompass offers a list of Reboxetine Mesylate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Reboxetine Mesylate manufacturer or Reboxetine Mesylate supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Reboxetine Mesylate manufacturer or Reboxetine Mesylate supplier.
PharmaCompass also assists you with knowing the Reboxetine Mesylate API Price utilized in the formulation of products. Reboxetine Mesylate API Price is not always fixed or binding as the Reboxetine Mesylate Price is obtained through a variety of data sources. The Reboxetine Mesylate Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Reboxetine Mesylate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Reboxetine Mesylate, including repackagers and relabelers. The FDA regulates Reboxetine Mesylate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Reboxetine Mesylate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Reboxetine Mesylate manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Reboxetine Mesylate supplier is an individual or a company that provides Reboxetine Mesylate active pharmaceutical ingredient (API) or Reboxetine Mesylate finished formulations upon request. The Reboxetine Mesylate suppliers may include Reboxetine Mesylate API manufacturers, exporters, distributors and traders.
click here to find a list of Reboxetine Mesylate suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
Reboxetine Mesylate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Reboxetine Mesylate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Reboxetine Mesylate GMP manufacturer or Reboxetine Mesylate GMP API supplier for your needs.
A Reboxetine Mesylate CoA (Certificate of Analysis) is a formal document that attests to Reboxetine Mesylate's compliance with Reboxetine Mesylate specifications and serves as a tool for batch-level quality control.
Reboxetine Mesylate CoA mostly includes findings from lab analyses of a specific batch. For each Reboxetine Mesylate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Reboxetine Mesylate may be tested according to a variety of international standards, such as European Pharmacopoeia (Reboxetine Mesylate EP), Reboxetine Mesylate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Reboxetine Mesylate USP).
Comment (9)
